Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK-1084 + cetuximab + mFOLFOX6 versus mFOLFOX6 with or without bevacizumab as first-line treatment for KRAS G12C-mutant metastatic colorectal cancer
CTR20253402Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of calderasib in colorectal adenocarcinoma, sponsored by Merck & Co.. Started Sep 2025; status: active.
02
Drugs
calderasib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20253402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253402.